Stay updated with breaking news from Nasdaq Tech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) have been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month […]
Bio-Techne (NASDAQ:TECH – Get Rating) and Ocugen (NASDAQ:OCGN – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation. Risk & Volatility Bio-Techne has a beta of 1.26, meaning that its […]
Quadrant Capital Group LLC grew its position in Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 267.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,556 shares of the biotechnology company’s stock after purchasing an additional 1,132 shares during the quarter. Quadrant Capital […]
Bio-Techne (NASDAQ:TECH – Get Rating) and Ocugen (NASDAQ:OCGN – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Risk & Volatility Bio-Techne has a beta of 1.25, suggesting that its […]
Simplify Asset Management Inc. lifted its holdings in shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 335.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,524 shares of the biotechnology company’s stock after purchasing an additional 3,484 shares […]